Opendata, web and dolomites

CARBALIVE SIGNED

Clinical evaluation of carbons of controlled porosity as a new therapeutic for the treatment of liver cirrhosis and non-alcoholic fatty liver disease.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "CARBALIVE" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITY COLLEGE LONDON 

Organization address
address: GOWER STREET
city: LONDON
postcode: WC1E 6BT
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.carbalive.eu/
 Total cost 6˙438˙786 €
 EC max contribution 5˙913˙079 € (92%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-PHC-2014-two-stage
 Funding Scheme RIA
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2019-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY COLLEGE LONDON UK (LONDON) coordinator 1˙281˙528.00
2    YAQRIT LIMITED UK (LONDON) participant 899˙748.00
3    ALPHA BIORESEARCH SL ES (MADRID) participant 764˙535.00
4    MAST CARBON INTERNATIONAL LTD UK (Basingstoke) participant 398˙495.00
5    FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA PT (LISBOA) participant 307˙182.00
6    ASSISTANCE PUBLIQUE HOPITAUX DE PARIS FR (PARIS) participant 297˙016.00
7    CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER ES (BARCELONA) participant 292˙056.00
8    ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA IT (BOLOGNA) participant 290˙506.00
9    FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA ES (BARCELONA) participant 289˙320.00
10    SERVICIO MADRILENO DE SALUD ES (MADRID) participant 278˙148.00
11    UNIVERSITA DEGLI STUDI DI PADOVA IT (PADOVA) participant 261˙399.00
12    EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC LIVER FAILURE (EF-CLIF) ES (BARCELONA) participant 238˙250.00
13    UNIVERSITY OF BRIGHTON UK (BRIGHTON) participant 179˙954.00
14    A2F ASSOCIATES LIMITED UK (NEWMARKET) participant 134˙936.00
15    UNIVERSITAET BERN CH (BERN) participant 0.00

Map

 Project objective

Chronic liver disease affects about 29-million Europeans accounting for about 170,000 deaths at a cost of around €15.8bn. This chronic non-communicable disease is increasing at an alarming rate due to increasing European obesity, alcohol use and ageing. The three main causes of the disease; alcohol, fatty liver and viral hepatitis are amenable to prevention and treatment. Gut-derived endotoxins and bacterial translocation are central factors implicated in the pathogenesis of fatty liver disease and, the development and progression of cirrhosis. In cirrhosis, current state-of-the-art therapy to prevent recurrent complications of advanced cirrhosis is to use poorly absorbed antibiotics but long-term antibiotic therapy has problems associated with bacterial resistance, infection with resistant organisms and the cost. Treatment of fatty liver and modulation of bacterial translocation in early cirrhosis to prevent complications is an unmet need. Our academic-industrial consortium has developed a novel, patented, safe and cheap nanoporous carbon that modulates the effects of bacterial translocation in animal models of liver disease. Our feasibility studies demonstrate that this product advances the current state-of-the-art, is a TRL 4/5 and is now ready for validation through clinical trials. We propose to investigate the safety and efficacy of this novel nanoporous carbon in patients with fatty liver disease and cirrhosis. If successful, we will be able to confirm an innovative, cost-effective and novel strategy for the management of this chronic disease in a European population. Exploitation of the results of the CARBALIVE project will support the continued development of this carbon through additional private and public sector investment. The use of this innovative therapy is expected to reduce the economic burden of the disease in Europe, allow patients to achieve enhanced quality of life, improve survival, and allow many patients to return to economic productivity.

 Deliverables

List of deliverables.
Project website and social media accounts Other 2020-04-09 08:15:12

Take a look to the deliverables list in detail:  detailed list of CARBALIVE deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Agustín Albillos, Andrea de Gottardi, María Rescigno
The gut-liver axis in liver disease: Pathophysiological basis for therapy
published pages: , ISSN: 0168-8278, DOI: 10.1016/j.jhep.2019.10.003
Journal of Hepatology 2020-04-09
2017 Reiner Wiest, Agustin Albillos, Michael Trauner, Jasmohan S. Bajaj, Rajiv Jalan
Targeting the gut-liver axis in liver disease
published pages: 1084-1103, ISSN: 0168-8278, DOI: 10.1016/j.jhep.2017.05.007
Journal of Hepatology 67/5 2020-04-09

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CARBALIVE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CARBALIVE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More